Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Apr 22;98(8):1301-4.
doi: 10.1038/sj.bjc.6604332. Epub 2008 Mar 25.

The role of S-1 in the treatment of gastric cancer

T Kubota  1
Affiliations
Review

The role of S-1 in the treatment of gastric cancer

T Kubota. Br J Cancer. .

Abstract

S-1 is a potent antitumour drug in gastric cancer. After years of disagreement about the utility of chemotherapy for advanced gastric cancer, several studies have recently demonstrated the efficacy of S-1 in both the adjuvant and primary settings. In this Minireview, the value of S-1 in the treatment of gastric cancer is discussed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The mode of action of S-1. S-1 is composed of tegafur (FT), 5-chloro-2, 4-dihydroxypyridine (gimestat [CDHP]), and oteracil potassium (Oxo) in a molar ratio of 1 : 0.4 : 1 to enhance the oral efficacy of FT, a prodrug of 5-fluorouracil (5-FU). CDHP inhibits the activity of dihydropyrimidine dehydrogenase (DPD), an enzyme that degrades 5-FU, with about 180-fold more potency than uracil. Oxo is distributed in the gastrointestinal tract at a high concentration following oral administration, and it prevents phosphorylation (i.e., activation) of 5-FU by inhibiting the effect of orotate phosphoribosyl transferase (OPRT).
See this image and copyright information in PMC

References

    1. Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Kimura A, Ohtsu A, Gastrointestinal Oncology Study Group/Japan Clinical Oncology Group (2007) Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). J Clin Oncol 25(18S): 965s (abstract LBA4513)
    1. Chu QS, Hammond LA, Schwartz G, Ochoa L, Rha SY, Denis L, Molpus K, Roedig B, Letrent SP, Damle B, DeCillis AP, Rowinsky EK (2004) Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. Clin Cancer Res 10(15): 4913–4921 - PubMed
    1. Japanese Gastric Cancer Association (2004) Guideline for Treatment of Gastric Cancer. Kanehara Shuppan: Tokyo
    1. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki Km, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T (1999) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5(8): 2000–2005 - PubMed
    1. Imamura H, Iishi H, Tsuburaya A, Hatake K, Imamoto H, Esaki T, Kato M, Furukawa H, Hamada C, Sakata Y (2008) Irinotecan plus S-l (IRI-S) versus S-l alone as first line treatment for advanced gastric cancer: results of a randomized phase III study (GC0301/TOP-002). ASCO-GI 2008: (abstract 5) www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst detail_view&conflD=53&abstractID=10303

MeSH terms